
News and Publications
Publication Categories
7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the Clinic
7 Hills Pharma has been awarded a $4.7 million CPRIT grant to advance 7HP935, a first-in-class small molecule gene therapy that enhances hematopoietic stem cell transplantation (HSCT). This therapy aims to improve stem cell engraftment and reduce infection risks, offering a better treatment option for cancer and genetic disorder patients, especially those from ethnic minorities with limited stem cell donor matches.
7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding
7 Hills Pharma has received a $13.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to advance 7HP349 (Alintegimod) into a Phase 1b/2a trial targeting PD-1-resistant solid tumors. This funding supports the development of a novel immunotherapy to overcome immune checkpoint inhibitor resistance, offering hope for checkpoint blockade-resistant patients.
7 Hills Pharma Receives $3MM SBIR Grant from NIAID to Accelerate Novel Vaccine Combination Against Chagas Disease
7 Hills Pharma receives a $3 million SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop the first vaccine for Chagas disease. This innovative vaccine combination with 7HP349 aims to protect millions from the Trypanosoma cruzi parasite and prevent severe outcomes of the disease.